−0.6943USD
−8.36 MUSD
8.48 M
About Cadrenal Therapeutics, Inc.
Sector
Industry
CEO
Quang X. Pham
Website
Headquarters
Ponte Vedra Beach
Employees (FY)
4
Founded
2022
ISIN
US1276361086
FIGI
BBG019STRT20
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CVKD is 0.4298 USD — it has increased by 1.92% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cadrenal Therapeutics, Inc. stocks are traded under the ticker CVKD.
Cadrenal Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
CVKD stock is 8.59% volatile and has beta coefficient of 1.78. Check out the list of the most volatile stocks — is Cadrenal Therapeutics, Inc. there?
One year price forecast for Cadrenal Therapeutics, Inc. has a max estimate of 4.0000 USD and a min estimate of 3.0000 USD.
CVKD earnings for the last quarter are −0.07 USD whereas the estimation was −0.07 USD which accounts for 0% surprise. Estimated earnings for the next quarter are −0.08 USD. See more details about Cadrenal Therapeutics, Inc. earnings.
Yes, you can track Cadrenal Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CVKD stock has risen by 5.21% compared to the previous week, the month change is a 23.25% fall, over the last year Cadrenal Therapeutics, Inc. has showed a 73.48% decrease.
CVKD net income for the last quarter is −1.14 M USD, while the quarter before that showed −1.04 M USD of net income which accounts for −10.38% change. Track more Cadrenal Therapeutics, Inc. financial stats to get the full picture.
No, CVKD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CVKD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cadrenal Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 4.00 employees. See our rating of the largest employees — is Cadrenal Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cadrenal Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cadrenal Therapeutics, Inc. stock shows the strong sell signal. See more of Cadrenal Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cadrenal Therapeutics, Inc. future price: according to them, CVKD price has a max estimate of 4.00 USD and a min estimate of 3.00 USD. Read a more detailed Cadrenal Therapeutics, Inc. forecast: see what analysts think of Cadrenal Therapeutics, Inc. and suggest that you do with its stocks.